<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8205">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000127</url>
  </required_header>
  <id_info>
    <org_study_id>1R01NS102295</org_study_id>
    <nct_id>NCT03000127</nct_id>
  </id_info>
  <brief_title>Testosterone for Fatigue in Men With MS</brief_title>
  <official_title>A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fatigue is a major symptom in people with multiple sclerosis (MS), for which treatments are
      limited. Several studies have shown that a large proportion of men with MS have low
      testosterone levels. We propose a two-site clinical trial using topical testosterone gel as
      a treatment for MS-related fatigue in men with progressive MS who have low or low-normal
      testosterone levels.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2017</start_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>18 months</time_frame>
    <description>assessment of fatigue severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Localized Gray Matter Atrophy</measure>
    <time_frame>18 months</time_frame>
    <description>Quantify effect of testosterone treatment on localized gray matter atrophy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axon Density in White Matter</measure>
    <time_frame>18 months</time_frame>
    <description>Quantify effect of testosterone treatment on axon density in major white matter tracts</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of testosterone level with fatigue</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of localized gray matter atrophy with fatigue</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of axon density in white matter with fatigue</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Single arm crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive testosterone gel and placebo gel during some months, but the months that they are on each treatment will be unknown to the patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AndroGel 1 % Topical Gel</intervention_name>
    <description>testosterone gel</description>
    <arm_group_label>Single arm crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo gel</description>
    <arm_group_label>Single arm crossover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Men with SPMS or PPMS, 2)18-60 years old, 3) EDSS of 1.0- 6.5, 4) Low or low-normal T &lt;
        499ng/dL and 5) FSS scores of &gt;3.6.

        Exclusion Criteria:

        1) Prostate specific antigen &gt; 2.5 (&lt;49yr of age) or &gt;3.5 (age &gt;50yr of age), 2) baseline
        hematocrit greater than the upper limit of normal for the laboratory used, 3) EKG with
        ischemic changes, 4) history of myocardial infarction, unstable angina, stroke, transient
        ischemic attack, or deep vein thrombosis, 5) history of prostate or breast cancer, 6)
        screening T level &gt;500ng/dL, 7) diabetes requiring treatment, 8) current drug/alcohol
        abuse, 9) disease other than MS causing fatigue, such as obstructive sleep apnea or other
        sleep disorder, or untreated thyroid dysfunction, 10) RRMS, 11) Beck Depression
        Inventory-II (BDI) score over 20, 12) cognitive dysfunction such that subject cannot
        perform study tests, 13) inability to undergo MRI, 14) current or expected use of
        amphetamines, or 15) anticipated changes in medical treatments that might affect fatigue
        scores (e.g., expected changes in spasticity, sleep, or depression medications).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mike Montag, M.S.</last_name>
      <phone>310-206-2176</phone>
      <email>MMontag@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Rhonda Voskuhl, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 17, 2016</lastchanged_date>
  <firstreceived_date>December 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Rhonda Voskuhl</investigator_full_name>
    <investigator_title>Professor, Department of Neurology</investigator_title>
  </responsible_party>
  <keyword>testosterone</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
